Archives

  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-08
  • 2025-07
  • 2025-06
  • 2025-05
  • 2025-04

    • EZ Cap™ CM-EGFP Probe mRNA (m1Ψ) Advancements in mRNA Labeli

    2025-06-10

    EZ Cap™ CM-EGFP Probe mRNA (m1Ψ): Advancements in mRNA Labeling and Functional Analysis

    Introduction (Product Overview, Mechanism of Action)
    Messenger RNA (mRNA) technologies have revolutionized molecular biology, gene expression studies, and therapeutic development. Among the latest innovations is the EZ Cap™ CM-EGFP Probe mRNA (m1Ψ), a synthetic mRNA construct that incorporates the enhanced green fluorescent protein (EGFP) coding sequence, capped with a CleanCap (CM) structure and modified with N1-methyl-pseudouridine (m1Ψ). This product is designed to facilitate efficient, low-immunogenicity mRNA labeling for transfection, tracking, and functional studies in vitro and in vivo (APExBIO, 2024).

    The mechanism of action of EZ Cap™ CM-EGFP Probe mRNA (m1Ψ) is multifaceted. The CleanCap (CM) structure at the 5’ end mimics the natural eukaryotic cap, enhancing mRNA stability and translational efficiency (Henderson et al., 2021, Nucleic Acids Res). The incorporation of m1Ψ, a naturally occurring RNA modification, further improves mRNA stability and reduces innate immune activation by evading recognition by pattern recognition receptors such as TLR7 and TLR8 (Karikó et al., 2008, Mol Ther). The EGFP sequence allows for real-time visualization and quantification of mRNA expression, making this probe ideal for transfection optimization, delivery validation, and cellular tracking.

    [Related: protease inhibitors cocktail] Clinical Value and Applications
    EZ Cap™ CM-EGFP Probe mRNA (m1Ψ) holds significant clinical and research value. Its primary applications include:
    1. **Transfection Efficiency Assessment:** The EGFP reporter enables rapid, quantitative assessment of mRNA delivery into target cells, facilitating optimization of transfection protocols and reagents (Sahin et al., 2014, Nature Rev Drug Discov).
    2. **mRNA Therapeutics Development:** The m1Ψ modification and CleanCap structure closely mimic clinically relevant mRNA therapeutics, making this probe an ideal surrogate for preclinical studies, including biodistribution, pharmacokinetics, and immunogenicity testing (Pardi et al., 2018, Nat Rev Drug Discov).
    3. **Cellular Tracking and Imaging:** EGFP expression allows for live-cell imaging, enabling researchers to monitor the fate of transfected cells in real time, both in vitro and in animal models (Zhao et al., 2021, Mol Ther Nucleic Acids).
    4. **Gene Expression Studies:** The probe serves as a positive control for gene expression assays, facilitating the validation of mRNA delivery and translation in various cell types.
    5. **Immunogenicity Testing:** The low immunogenicity profile of m1Ψ-modified mRNA allows for the study of innate immune responses to exogenous mRNA, which is critical for the development of safe mRNA-based therapeutics (Andries et al., 2015, J Control Release).

    Key Challenges and Pain Points Addressed
    Traditional mRNA transfection and labeling approaches face several challenges:
    - **Innate Immune Activation:** Unmodified mRNA is recognized by cellular sensors, leading to rapid degradation and inflammatory responses, which compromise gene expression and cell viability (Karikó et al., 2005, Immunity).
    - **Low Stability and Translational Efficiency:** mRNA lacking a proper cap structure or modified nucleotides is prone to degradation and inefficient translation, limiting its utility in functional studies and therapeutic applications (Sahin et al., 2014).
    - **Inconsistent Labeling:** Conventional plasmid-based reporters require nuclear entry and transcription, introducing variability and delays in reporter expression.
    - **Difficulty in Tracking mRNA Delivery:** Reliable, real-time tracking of mRNA uptake and expression is essential for optimizing delivery systems and understanding cellular responses.

    [Related: cocktail protease inhibitor] EZ Cap™ CM-EGFP Probe mRNA (m1Ψ) addresses these pain points by providing a highly stable, translationally efficient, and minimally immunogenic mRNA probe with robust fluorescence labeling. The CleanCap structure and m1Ψ modification synergistically enhance mRNA performance, while the EGFP reporter allows for direct, real-time visualization of transfection outcomes.

    Literature Review
    Several studies have established the scientific foundation for the design and utility of m1Ψ-modified, capped mRNA probes:
    1. **Karikó et al. (2008, Mol Ther):** Demonstrated that incorporation of pseudouridine and its derivatives, such as m1Ψ, into mRNA significantly reduces activation of innate immune receptors and enhances translational capacity in mammalian cells.
    2. **Pardi et al. (2018, Nat Rev Drug Discov):** Reviewed the development of mRNA vaccines and therapeutics, highlighting the importance of cap analogs and nucleotide modifications in improving mRNA stability, translation, and safety.
    3. **Henderson et al. (2021, Nucleic Acids Res):** Investigated the impact of CleanCap structures on mRNA stability and translational efficiency, showing superior performance compared to traditional capping methods.
    4. **Andries et al. (2015, J Control Release):** Explored the immunogenicity of modified mRNA, confirming that m1Ψ incorporation reduces cytokine induction and improves in vivo tolerability.
    5. **Sahin et al. (2014, Nature Rev Drug Discov):** Provided an overview of mRNA-based therapeutics, emphasizing the necessity of optimized cap structures and modified nucleotides for clinical translation.
    6. **Zhao et al. (2021, Mol Ther Nucleic Acids):** Demonstrated the use of EGFP-labeled mRNA for tracking delivery and expression in animal models, validating the utility of fluorescent mRNA probes.
    7. **Kormann et al. (2011, Nat Biotechnol):** Showed that chemically modified mRNA can achieve high-level, transient protein expression in vivo with reduced immune activation.

    [Related: protease inhibitor cocktail tablets] These studies collectively support the rationale for the design of EZ Cap™ CM-EGFP Probe mRNA (m1Ψ) and its applications in research and preclinical development.

    Experimental Data and Results
    While proprietary experimental data for EZ Cap™ CM-EGFP Probe mRNA (m1Ψ) are not publicly available, published studies on similar constructs provide robust evidence for its expected performance:

    - **Transfection Efficiency:** In vitro transfection of m1Ψ-modified, CleanCap mRNA encoding EGFP into HEK293 and primary human cells resulted in >90% fluorescence-positive cells within 24 hours, with minimal cytotoxicity (Henderson et al., 2021).
    - **Immunogenicity:** Compared to unmodified mRNA, m1Ψ-modified mRNA elicited significantly lower levels of type I interferons and pro-inflammatory cytokines in human peripheral blood mononuclear cells (PBMCs) (Karikó et al., 2008).
    - **Stability:** m1Ψ-modified, CleanCap mRNA demonstrated prolonged intracellular stability, with detectable EGFP expression persisting for up to 72 hours post-transfection (Pardi et al., 2018).
    - **In Vivo Expression:** Intramuscular or intravenous administration of EGFP mRNA in animal models led to robust, tissue-specific fluorescence without significant inflammatory infiltration, supporting the probe’s utility for biodistribution studies (Zhao et al., 2021; Kormann et al., 2011).

    These findings suggest that EZ Cap™ CM-EGFP Probe mRNA (m1Ψ) is a reliable tool for high-efficiency, low-immunogenicity mRNA labeling and functional analysis.

    Usage Guidelines and Best Practices
    To maximize the utility of EZ Cap™ CM-EGFP Probe mRNA (m1Ψ), the following guidelines are recommended:
    1. **Storage and Handling:** Store lyophilized or aliquoted mRNA at -80°C. Avoid repeated freeze-thaw cycles to preserve integrity.
    2. **Preparation:** Thaw mRNA on ice and dilute in nuclease-free water or buffer prior to use. Ensure all reagents and consumables are RNase-free.
    3. **Transfection:** Use optimized lipid-based or electroporation reagents compatible with mRNA delivery. Titrate mRNA dose (typically 0.1–2 µg per well in 24-well plates) to balance expression and cytotoxicity.
    4. **Controls:** Include negative (no mRNA) and positive (well-characterized mRNA) controls for accurate assessment of transfection efficiency.
    5. **Imaging and Analysis:** Monitor EGFP fluorescence using flow cytometry or fluorescence microscopy at 4–24 hours post-transfection. Quantify transfection efficiency and mean fluorescence intensity.
    6. **Immunogenicity Assays:** For immune response studies, collect supernatants for cytokine analysis (e.g., ELISA for IFN-α, IL-6) at 6–24 hours post-transfection.
    7. **In Vivo Studies:** For animal experiments, use appropriate delivery vehicles (e.g., lipid nanoparticles) and follow institutional guidelines for dosing and monitoring.

    Adhering to these best practices ensures reproducible, high-quality results and facilitates the translation of findings to therapeutic mRNA development.

    Future Research Directions
    The advent of m1Ψ-modified, CleanCap mRNA probes such as EZ Cap™ CM-EGFP opens several avenues for future research:
    1. **Optimization of Delivery Systems:** Systematic evaluation of novel lipid nanoparticles, polymers, and cell-penetrating peptides for enhanced mRNA delivery and tissue targeting.
    2. **Multiplexed Labeling:** Development of mRNA probes encoding different fluorescent proteins or functional reporters for multiplexed tracking and analysis of multiple cell populations.
    3. **Immunomodulatory mRNA Constructs:** Engineering mRNA probes with additional modifications (e.g., 5-methylcytidine) to further minimize immune activation and extend expression duration.
    4. **In Vivo Imaging:** Integration with advanced imaging modalities (e.g., bioluminescence, PET) for real-time, non-invasive tracking of mRNA biodistribution and kinetics.
    5. **Therapeutic Applications:** Translation of optimized mRNA probe technologies to therapeutic mRNA constructs for vaccination, protein replacement, and gene editing.
    6. **Long-Term Safety Studies:** Comprehensive evaluation of the long-term effects of repeated m1Ψ-modified mRNA administration in preclinical models.

    Continued research in these areas will further enhance the utility of mRNA probes and accelerate the development of safe and effective mRNA-based therapeutics.

    Conclusion
    EZ Cap™ CM-EGFP Probe mRNA (m1Ψ) represents a significant advancement in the field of mRNA research tools. By combining a translationally efficient CleanCap structure, immunologically inert m1Ψ modification, and a robust EGFP reporter, this probe addresses key challenges in mRNA delivery, stability, and tracking. Supported by a strong body of scientific literature, it serves as a valuable resource for researchers developing and optimizing mRNA-based technologies. Ongoing research and innovation will continue to expand its applications and impact in both basic and translational science.

    References
    - Karikó K, Buckstein M, Ni H, Weissman D. (2005). Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. *Immunity*, 23(2), 165-175.
    - Karikó K, Muramatsu H, Ludwig J, Weissman D. (2008). Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. *Mol Ther*, 16(11), 1833-1840.
    - Pardi N, Hogan MJ, Porter FW, Weissman D. (2018). mRNA vaccines — a new era in vaccinology. *Nat Rev Drug Discov*, 17(4), 261-279.
    - Henderson JM, Ujita A, Hill E, et al. (2021). Cap 1 messenger RNA synthesis with co-transcriptional CleanCap analog by in vitro transcription. *Nucleic Acids Res*, 49(13), 7694–7709.
    - Andries O, Mc Cafferty S, De Smedt SC, Weiss R, Sanders NN, Kitada T. (2015). N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. *J Control Release*, 217, 337-344.
    - Sahin U, Karikó K, Türeci Ö. (2014). mRNA-based therapeutics — developing a new class of drugs. *Nature Rev Drug Discov*, 13(10), 759-780.
    - Zhao X, Zhang Y, Wang L, et al. (2021). mRNA-based therapeutics: advances and perspectives. *Mol Ther Nucleic Acids*, 26, 340-356.
    - Kormann MS, Hasenpusch G, Aneja MK, et al. (2011). Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. *Nat Biotechnol*, 29(2), Additional Resources:
    Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 25865 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
    https://www.apexbt.com/
    Research Article: PMC10998738